Browse the latest research summaries in the field of immunology for spinal cord injury patients and caregivers.
Showing 371-380 of 730 results
Neurobiol Dis., 2016 • September 1, 2016
The study demonstrates that the thrombin receptor (PAR1) is a critical regulator of inflammation and astrogliosis after traumatic SCI. Targeting PAR1 genetically improved neurobehavioral outcomes, red...
KEY FINDING: PAR1 knockout mice displayed improved locomotor recovery after SCI and reduced signatures of inflammation and astrogliosis.
The Journal of Spinal Cord Medicine, 2017 • July 4, 2017
This study aimed to determine the association between pneumonia and pressure ulcers (PUs) in individuals with spinal cord injury (SCI) during acute care and rehabilitation. The study found a significa...
KEY FINDING: Individuals with pneumonia had a significantly higher presence of pressure ulcers compared to those without pneumonia in both acute care and inpatient rehabilitation settings.
Exp Neurol, 2016 • August 1, 2016
This study investigates the remote effects of thoracic spinal cord injury (SCI) on the lumbar region, focusing on myeloid cell infiltration and its impact on locomotor networks. The findings reveal th...
KEY FINDING: Myeloid cell infiltration occurs in the lumbar cord, but not the cervical region, after thoracic SCI.
Medicine, 2014 • December 1, 2014
This study analyzed a large claims database to compare the effectiveness of different oral antibiotics for urinary tract infections (UTIs) in outpatients. The results suggest that norfloxacin and oflo...
KEY FINDING: Norfloxacin had the lowest treatment failure rate compared to TMP-SMX in crude estimate (OR, 0.73; 95% CI, 0.57–0.94), individual covariate adjustment (OR, 0.70; 95% CI, 0.54–0.90), and propensity score matched analysis (OR, 0.73; 95% CI, 0.54–1.00).
Ann Rehabil Med, 2016 • August 26, 2016
This retrospective study investigated risk factors for urinary tract infection (UTI) following urodynamic study (UDS) in 140 spinal cord injury (SCI) patients receiving prophylactic antibiotics. The k...
KEY FINDING: A history of UTI within the past 4 weeks prior to the UDS was significantly associated with UTI occurrence after the UDS, even with prophylactic antibiotic therapy (p=0.006).
Journal of Neuroinflammation, 2016 • September 7, 2016
The study explored the antibody signature of SCI patients using SAS, identifying 19 distinct antigenic targets with increased reactivity in SCI patients compared to healthy controls. Reactivity toward...
KEY FINDING: Nineteen antigenic targets with increased reactivity in SCI patients were identified using serological antigen selection (SAS).
BMC Neurology, 2016 • August 26, 2016
This prospective study investigates the influence of SCI on NK cell activity, considering disease phases and lesion level dependency. The study hypothesizes that SCI impairs NK cell function, and this...
KEY FINDING: The primary endpoint of the study is CD107a expression by NK cells (cytotoxicity marker) 8–12 weeks following SCI.
Journal of Visualized Experiments, 2016 • September 12, 2016
The study presents a protocol to differentiate between immune system suppression and CNS protection for pharmacological interventions in autoimmune demyelination. It utilizes EAE models in mice, combi...
KEY FINDING: The protocol differentiates between treatments that suppress the immune system and those that directly protect the CNS during autoimmune demyelination.
Int. J. Mol. Sci., 2015 • April 9, 2015
This study measured serum cytokine levels in 40 acute traumatic SCI patients over 12 weeks to assess their impact on neurological outcome. The study found that specific cytokines (TNFα, IL-1β, IL-6, I...
KEY FINDING: TNFα, IL-1β, IL-6, IL-8, and IL-10 concentrations were significantly higher in patients without neurological remission.
Brazilian Journal of Infectious Diseases, 2016 • October 18, 2016
This retrospective study evaluated the effectiveness of different antibiotic protocols in preventing urinary tract infections (UTIs) in patients with neurogenic bladder undergoing botulinum toxin A (B...
KEY FINDING: The study found a low overall rate of symptomatic UTIs (1.8%) among patients receiving botulinum toxin A injections for neurogenic bladder.